6月10日 - ** 制药商InsmedINSM.O股价盘前上涨24.9%至88.28美元
** 该公司称其 treprostinil palmitil 吸入粉(TPIP) 在一项中期试验中达到了 (link) 的主要目标，与安慰剂相比，肺部血流阻力降低了 35
** 该药物在肺动脉高压（Pulmonary Arterial Hypertension）患者(PAH) 中进行了测试，这是一种由于肺部动脉收缩导致高血压的罕见疾病。
** 该公司称，这种治疗药物通过胶囊吸入装置每日给药一次。
** INSM 表示计划在 2026 年初启动该药物的后期试验
** 截至上日收盘，股价累计上涨2.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.